Product Center
Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine marketing application has been accepted by the National Medical Products Administration!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21
- Views:
(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accep
Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine marketing application has been accepted by the National Medical Products Administration!
(Summary description)Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accep
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-03-21 16:16
- Views:
Recently, Ab&B Bio Tech CO., LTD. JS independently developed a market application for the unadjuvant quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted by the National Medical Products Administration (NMPA) of China. This is the first market application for a quadrivalent influenza virus subunit vaccine accepted by NMPA.
Source: CDE website
The Ab&B Bio Tech CO., LTD. JS quadrivalent influenza virus subunit vaccine is a component vaccine containing a new antigen form, characterized by high purity, low vaccination side effects, and good safety. In 2016, the company applied for clinical trials of the quadrivalent influenza virus subunit vaccine using its own patented technology. In 2017, the company obtained clinical approval for two biological product class I new drugs in adult and child dosage forms. From 2018 to 2021, the phase I/III clinical trial was successfully completed, and all relevant trial results reached clinical endpoints, showing significant positive results in immunogenicity and safety. The clinical results show that the full dose unadjuvant (0.5ml) quadrivalent influenza virus subunit vaccine for individuals aged 3 and above, which has been accepted for the company's listing application, is a safe and effective influenza vaccine that can provide broader and sufficient protection against seasonal influenza viruses. This vaccine is expected to serve as an important member of the influenza prevention strategy and contribute China's efforts to the global prevention and control of influenza virus outbreaks and infections.
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
